{
    "clinical_study": {
        "@rank": "36727", 
        "arm_group": [
            {
                "arm_group_label": "SC HZ/su Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule."
            }, 
            {
                "arm_group_label": "IM HZ/su Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK\n      Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC)\n      as compared to intramuscularly (IM) to people 50 years of age and older."
        }, 
        "brief_title": "Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine When Administered Under the Skin (Subcutaneously) vs. Into a Muscle (Intramuscularly) in Adults 50 Years of Age and Older", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "detailed_description": {
            "textblock": "There are 2 treatment groups in this study based upon the mode of vaccine administration.\n\n      The humoral immunogenicity (HI) will be measured in all subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  Subject, residing in Japan, is of Japanese ethnic origin, defined as having been born\n             in Japan with four ethnic Japanese grandparents and able to speak Japanese.\n\n          -  Subject has provided written informed consent.\n\n          -  Subject, male or female, who is 50 YOA or older at the time of the first vaccination.\n\n          -  Subject, if female, of non-childbearing potential may be enrolled in the study.\n\n          -  Subject, if female, of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series (i.e., for 2 months\n                  after Month 2).\n\n          -  Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccine within 30 days preceding the first dose of study vaccine, or planned\n             use during the study period.\n\n          -  Concurrently participating or planned participation in another clinical study, at any\n             time during the study period, in which the subject has been or will be exposed to an\n             investigational or a non-investigational product.\n\n          -  Administration or planned administration of a live vaccine within 30 days prior to\n             the first study vaccination through 30 days after the second study vaccination.\n\n          -  Administration or planned administration of a non-replicating vaccine within 8 days\n             prior to or within 14 days after either dose of study vaccine.\n\n          -  Planned administration, during the study, of an HZ or varicella vaccine (including an\n             investigational or non-registered vaccine) other than the study vaccine.\n\n          -  Administration of immunoglobulins and/or any blood products within the three (3)\n             months preceding the first dose of study vaccine or planned administration during the\n             study period.\n\n          -  Chronic administration (defined as >14 consecutive days) of immunosuppressants or\n             other immune-modifying drugs within six months prior to the first vaccine dose.\n\n               -  For corticosteroids, a prednisone dose of <20 mg/day, or equivalent, is allowed.\n\n               -  Inhaled, topical, and intra-articular corticosteroids are allowed.\n\n          -  Administration or planned administration of long-acting immune-modifying drugs (e.g.,\n             infliximab) within six months prior to the first vaccine dose through the duration of\n             the study period.\n\n          -  History of HZ.\n\n          -  Previous vaccination against HZ or varicella (registered or investigational product).\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccine or study material and equipment.\n\n          -  Significant underlying illness that, in the opinion of the investigator, would be\n             expected to prevent completion of the study.\n\n          -  Any other condition that, in the opinion of the investigator, might interfere with\n             the evaluations required by the study.\n\n          -  Acute disease and/or fever at the time of vaccination:\n\n               -  Fever is defined as temperature \u226537.5\u00b0C (99.5\u00b0F) for oral, axillary, or tympanic\n                  route, or \u226538.0\u00b0C/100.4\u00b0F for rectal route. The preferred route for recording\n                  temperature in this study will be oral.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions (if of childbearing potential) through Month 4 (i.e., 2 months after the\n             second dose of study vaccine)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777321", 
            "org_study_id": "116760", 
            "secondary_id": "2012-005671-14"
        }, 
        "intervention": {
            "arm_group_label": [
                "SC HZ/su Group", 
                "IM HZ/su Group"
            ], 
            "description": "HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.", 
            "intervention_name": "Herpes zoster vaccine GSK1437173A", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Herpes Zoster", 
            "Intramuscular", 
            "Subcutaneous", 
            "Safety", 
            "\u226550 years of age", 
            "Adults", 
            "Immunogenicity", 
            "Elderly"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka", 
                    "country": "Japan", 
                    "zip": "812-0025"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously vs. Intramuscularly in Adults Aged \u226550 Years", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Japan: Ministry of Health, Labor and Welfare"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Evaluation of gE-specific antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "At one month post-vaccination 2 (Month 3)"
            }, 
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days (Days 0-6) after each vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 30 days (Days 0-29) after each vaccination"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "From Month 0 (vaccination 1) up to Month 3 (30 days post-vaccination 2)"
            }, 
            {
                "description": "In all subjects", 
                "measure": "Occurrence of adverse events (AEs) of specific interest [Potential Immune-Mediated Disease (pIMDs)]", 
                "safety_issue": "No", 
                "time_frame": "From Month 0 (vaccination 1) up to Month 3 (30 days post-vaccination 2)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluated in all subjects and for each cohort: Japanese and non-Japanese Ethnic Origin (JEOc and NJEOc)", 
                "measure": "Evaluation of gE-specific antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "Month 0 (prior to vaccination 1), Month 2 (2 months post-vaccination 1), Month 3 (one month post-vaccination 2) and Month 14 (12 months post-vaccination 2)"
            }, 
            {
                "description": "Evaluated in all subjects", 
                "measure": "Evaluation of gE-specific antibody concentrations", 
                "safety_issue": "No", 
                "time_frame": "Month 2 (2 months post-vaccination 1), Month 3 (one month post-vaccination 2) and Month 14 (12 months post-vaccination 2)"
            }, 
            {
                "description": "Evaluated for all subjects", 
                "measure": "Occurrence of SAEs", 
                "safety_issue": "No", 
                "time_frame": "From Month 3 (30 days post-vaccination 2) up to Month 14 (12 months post-vaccination 2)"
            }, 
            {
                "description": "Evaluated for all subjects", 
                "measure": "Occurrence of AEs of specific interest (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "From Month 3 (30 days post-vaccination 2) up to Month 14 (12 months post-vaccination 2)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}